Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 72Leucovorin 71Oxaliplatin 47Irinotecan 31Capecitabine 24Bevacizumab 23Folfox protocol 20Cetuximab 15Chemotherapy, Adjuvant 13Celecoxib 7Aspirin 6Laparoscopy 5XELOX 4Panitumumab 4Neoadjuvant Therapy 4Levamisole 4dehydroftorafur 3Tegafur 3Surgical Procedures, Operative 3Observation 3Floxuridine 3vatalanib 2tislelizumab 2pertuzumab 2encorafenib 2atezolizumab 2Trastuzumab 2Standard of Care 2Semaxinib 2Selenium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colonic Neoplasms × dostarlimab × Clear all
NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GlaxoSmithKline

Phase 3 Recruiting
892 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡